chevron_leftBack
As of 24 April 2025, Circio Holding ASA has a market cap of $5.52M USD, ranking #35497 globally and #235 in Norway. It ranks #3570 in the Healthcare sector, and #1189 in the Biotechnology industry.
Key Stats
Market Cap
$5.52MUSD
57.39M NOK
Enterprise Value
$5.36MUSD
56.41M NOK
EBITDA (TTM)
-$3.87MUSD
-40.72M NOK
Net Income (TTM)
$5.53MUSD
57.52M NOK
PE Ratio
0.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Erik Wiklund
open_in_new
Employees
10
Founded
2010
Website
circio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1.6% | 3% | 17% | -7.1% | -6.3% | -75% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
CRNA
ISIN: NO0013033795
Shares Out.:
Shares Outstanding:
84.144M1
Shares Float:
72.261M2
|
0.6500 NOK | |
|
TRVXO
(CRNAO)
Circio Holding ASA
ISIN: NO0013033795
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.6460 NOK |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a collaboration with Certest Biotec, S.L. for formulation of circVec into lipid nanoparticles. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. The company was incorporated in 2010 and is based in Oslo, Norway.
